Understanding Wegovy dosing: a clear guide

Wegovy follows a fixed dose-escalation schedule, starting at 0.25 mg weekly and building to a 2.4 mg maintenance dose over about four months. Below is what that schedule looks like, why it works that way, and what to ask your doctor before you start. , - Wegovy (semaglutide) is a prescription weight-loss medication with a dosing schedule that can look complicated on first read. Why does it take four months to reach the full dose? What happens if you miss an injection? Is there a higher dose now? This guide covers the approved schedule step by step, explains the reasoning behind it, and outlines questions worth raising with your prescriber before you begin. This article is general health information, not a substitute for a conversation with your clinician, and it does not apply to every person or situation.

Wegovy is a GLP-1 receptor agonist, a class of medication that works by mimicking a hormone involved in appetite regulation and blood sugar control. It is available by prescription only and is approved for chronic weight management in adults, as well as for a specific liver condition discussed later in this guide. The gradual dose escalation exists for a practical reason: the most common side effects, particularly nausea, vomiting, and other gastrointestinal symptoms, are dose-dependent. Starting low and moving up slowly gives the body time to adjust, which makes the medication more tolerable for most people. The early doses are not weight-loss doses. The 0.25 mg starting dose and the steps that follow are tolerance-building steps. The therapeutic dose for weight management is 2.4 mg. Expecting significant weight loss during the first few months of titration may lead to unnecessary discouragement.

The table below shows the approved titration schedule. Each phase lasts exactly four weeks. | Phase | Weeks | Dose | |---|---|---| | Initiation | 1 to 4 | 0.25 mg once weekly | | Step 1 | 5 to 8 | 0.5 mg once weekly | | Step 2 | 9 to 12 | 1.0 mg once weekly | | Step 3 | 13 to 16 | 1.7 mg once weekly | | Maintenance | 17 onward | 2.4 mg once weekly | You start at the lowest dose for a month, increase at the beginning of each subsequent month, and reach 2.4 mg at the start of month five. Do not increase your dose earlier than scheduled without explicit guidance from your prescriber. Moving up too quickly raises the risk of significant side effects. If a particular dose step causes side effects that are difficult to manage, escalation can be delayed at your prescriber's direction. This is an accepted approach in the prescribing guidance, not a sign that the medication is not working or that you have done something wrong. Contact your prescriber if you are struggling at a given step.

In early 2026, the FDA approved a higher maintenance dose of Wegovy at 7.2 mg once weekly. This dose is intended for patients who have reached and tolerated the 2.4 mg maintenance dose but need additional weight loss. The 7.2 mg dose was approved in the European Union and United Kingdom before receiving FDA approval in March 2026, with a US launch expected in April 2026. As of early 2026, it is not yet broadly available across all US pharmacies, and insurance coverage varies. Availability, coverage, and clinical protocols for the 7.2 mg dose are still being established. If you are interested in whether this option applies to you, confirm current availability and coverage directly with your prescriber and pharmacist.

Wegovy is a subcutaneous injection only. It should never be injected into a muscle or a vein. Approved injection sites are the abdomen, the thigh, and the upper arm. Rotating among these sites with each injection helps reduce local skin reactions such as redness or irritation. Wegovy can be taken with or without food. Injecting on the same day each week is recommended to keep a consistent schedule. If you need to shift your injection day, that is possible as long as your last dose was at least 48 hours before the new day. If you are self-injecting for the first time, ask your prescriber or a nurse to walk you through the technique. Proper injection method matters for both comfort and effectiveness.

Missing an occasional dose happens. Here is what to do: If your next scheduled dose is more than 48 hours away, take the missed dose as soon as you remember, then return to your regular weekly schedule. If your next scheduled dose is less than 48 hours away, skip the missed dose entirely and resume your regular schedule on the next scheduled day. Do not take two doses to make up for the one you missed. If you have missed two or more consecutive doses, contact your healthcare provider before resuming. You may need to restart dose escalation from a lower step to avoid side effects.

Beyond weight management, Wegovy has received accelerated approval for adults with metabolic dysfunction-associated steatohepatitis, commonly called MASH, when accompanied by moderate to advanced liver fibrosis (fibrosis stages F2 to F3). This is a distinct indication, and patients should discuss with their clinician which indication applies to their situation and whether it affects monitoring or follow-up. The dosing schedule for MASH is the same as for weight management: titrate to 2.4 mg maintenance using the standard step-up schedule. Wegovy is not approved for patients with cirrhosis (F4 fibrosis) or severe liver damage. If you have a history of liver disease, your clinician needs the full picture before prescribing.

The following highlights key safety points and is not a substitute for the full prescribing information. Do not use Wegovy if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This is a firm contraindication. Do not combine Wegovy with other semaglutide-containing products or with other GLP-1 receptor agonists. Serious side effects include possible thyroid tumors, pancreatitis, gallbladder disease, low blood sugar (particularly if you are also taking other diabetes medications that affect blood sugar), and kidney injury. Wegovy requires ongoing clinician supervision throughout treatment, not just at the point of the initial prescription. Regular follow-up matters.

The following is a checklist of topics worth raising before and during treatment. It is not exhaustive.

Whether the standard titration schedule is appropriate for you, or whether a slower escalation makes sense given your health history

What to do if GI side effects are significant at a given dose step

Whether the 7.2 mg dose is available, covered by your insurance, and appropriate for your situation

Which indication applies to you (weight management or MASH) and whether that affects monitoring

Your full medication list, to check for interactions, particularly other diabetes medications that affect blood sugar

Injection technique, especially if you are self-injecting for the first time

What monitoring (lab work, follow-up visits) your prescriber expects during titration and maintenance

What stopping Wegovy looks like if needed, and whether dose tapering is recommended in your case

This article reflects dosing information available as of early 2026. The 7.2 mg dose approval and rollout are recent, and details may change. Dosing in people under 18 is not covered in depth here. Safety and efficacy data in adolescents are limited, and guidance in this area is still developing. A pediatric specialist or endocrinologist is the right resource for questions about younger patients. This guide does not cover every contraindication, drug interaction, or individual clinical scenario. Defer to your prescriber and the current FDA-approved prescribing information for decisions about your care.